We are developing the promise of endoxifen and exploiting its potential to both help prevent as well as to treat breast cancer with our proprietary Topical and Oral Endoxifen.
We are developing proprietary intraductal microcatheter technology for the potential delivery of drugs and immunotherapies (such as CAR-T) through the breast ducts directly to the site of the cancer.
We work with organizations throughout the world to move our programs forward in an efficient and cost-effective manner.
We work with organizations throughout the world to move our programs forward in an efficient and cost-effective manner.
